secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0000950170-25-072965
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics shareholders double authorized shares to 326M; approve equity plan amendment
--------------------------------------------------------------------------------

- Authorized common stock increased from 163M to 326M shares, approved with 107.3M votes for, 3.0M against.
- Equity incentive plan amended to add 5.0M authorized shares and cap non-executive director grants ($1M annual, $1.25M initial).
- Elected Class III directors John T. Henderson, B. Lynne Parshall, and Muna Bhanji with majority support.
- Ratified Ernst & Young as independent auditor for FY2025 with 110.3M votes for.
- Advisory vote on executive compensation passed with 96.8M votes for, 4.6M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025072965/0000950170-25-072965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017025072965/cytk-20250514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-072965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer